Gambaran Profil Hematologi Rutin Pasien TB Paru Sebelum dan Sesudah Pengobatan dengan Obat Antituberkulosis
Abstract
Background: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M.tb) which often attacks the lung parenchyma and can also attack other organs. Changes can be found in the hematological profile of TB patients both at the time of diagnosis and after treatment.
Objective: This study was conducted to obtain routine hematological profiles of pulmonary TB patients before and after treatment with anti-tuberculosis drugs for 3 months, 4 months, and 5 months.
Methods: This study was an observational descriptive study. The population in this study was pulmonary TB patients at Martha Friska Hospital and Hermina Medan Hospital for the period October 2021-August 2022. The samples in this study were taken from medical record data of all pulmonary TB patients at Martha Friska Hospital and Hermina Medan Hospital for the period of October 2021-August 2022 (total sampling).
Results: In this study, 39 research subjects were obtained, age range of 15-79 years. Before treatment, the majority of patients had anemia (76.92%), leukocytosis (61.54%), normal platelets (66.67%), and elevated ESR (53.85%). After 3 months of treatment, anemia was experienced by 30%, leukocytosis by 0%, normal platelets by 80%, and elevated ESR by 20% of patients. After 4 months of treatment, anemia was experienced by 52.17%, leukocytosis by 4.35%, normal platelets by 65.22%, and elevated ESR by 4.35% of patients. After 5 months of treatment, anemia was experienced by 50%, leukocytosis by 0%, platelets normal by 83.33%, and elevated ESR by 0% of patients.
Conclusion: The majority of patients develop anemia, leukocytosis, and elevated ESR before treatment with antituberculosis drugs. There was a decrease in the proportion of patients who developed anemia, leukocytosis, and an elevated ESR after treatment with antituberculosis drugs for 3 months, 4 months, and 5 months.
References
2. World Health Organization. Global tuberculosis report 2020, https://www.who.int/publications/i/item/9789240013131 (2020, accessed 14 Maret 2022).
3. Badan Pusat Statistik Provinsi Sumatera Utara. Jumlah Kasus Penyakit Menurut Kabupaten/Kota dan Jenis Penyakit di Provinsi Sumatera Utara 2020, https://sumut.bps.go.id/statictable/2021/04/21/2219/jumlah-kasus-penyakit-menurut-kabupaten-kota-dan-jenis-penyakit-di-provinsi-sumatera-utara-2020.html (accessed 14 Maret 2022).
4. Banerjee M, Chaudhary BL, Shukla S. Hematological profile among pulmonary tuberculosis patients in tertiary care hospital. 2015; 3900–3902.
5. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. 2020.
6. Nurhayati E, Mulyanto A, Sudarsono TA, Wijaya L. Perbandingan kadar Hb sebelum dan sesudah pengobatan oat fase intensif pada penderita tuberkulosis paru di Puskesmas Petanahan Kebumen Tahun 2021. Jurnal Surya Medika. 2023; 9: 250–259.
7. Karwiti W, Sri Lestari W, Rezekiyah S. Perbedaan profil hematologi pada penderita tuberkulosis paru yang menjalani pengobatan. Jambura Journal of Health Sciences and Research. 2021;3(1):126-132.
8. Kalma K, Rafika R, Bahctiar AR. Platelet and hemoglobin concentration in tuberculosis patients with anti-tuberculosis medication. Jurnal Media Analis Kesehatan. 2019; 10: 143.
9. Khaironi S, Rahmita M, Siswani M. Gambaran jumlah leukosit dan jenis leukosit pada pasien tuberkulosis paru sebelum pengobatan dengan setelah pengobatan satu bulan intensif di Puskesmas Pekanbaru. J Anal Kesehat Klin Sains. 2017; 5: 68–70.
10. Sadewo SW, Salam A, Rialita A. Gambaran Status Anemia pada Pasien Tuberkulosis Paru. Jurnal Cerebellum. 2016;2(3):590-600
11. de Mendonça EB, Schmaltz CAS, Sant’Anna FM, Vizzoni AG, Mendes-de-Almeida DP, de Oliveira RVD. Anemia in tuberculosis cases: A biomarker of severity? PLoS One; 16. Epub ahead of print 1 February 2021. DOI: 10.1371/journal.pone.0245458.
12. Hella J, Cercamondi CI, Mhimbira F, Sasamalo M, Stoffel N, Zwahlen M. Anemia in tuberculosis cases and household controls from Tanzania: Contribution of disease, coinfections, and the role of hepcidin. PLoS One; 13. Epub ahead of print 1 April 2018. DOI: 10.1371/journal.pone.0195985.
13. Županić-Krmek, Sučić M, Bekić D. Anemia of chronic disease: illness or adaptive mechanism. Acta Clinica Croatia 2014; 53: 348–354.
14. Weiss G. Iron metabolism in the anemia of chronic disease. Biochimica et Biophysica Acta (BBA) - General Subjects. 2009; 1790: 682–693.
15. Shah A, Desai K, Maru A. Evaluation of hematological parameters in pulmonary tuberculosis patients. J Family Med Prim Care. 2022; 11: 4424.
16. Munasir Z. Respons imun terhadap infeksi bakteri. Sari Pediatri. 2001; 2: 193–197.
17. Sezer M, Ozturk A, Ilvan A, et al. The hemostatic changes in active pulmonary tuberculosis. Turkish Journal of Hematology. 2001; 18: 95–100.
18. Feng Y, Yin H, Mai G, et al. Elevated serum levels of CCL17 correlate with increased peripheral blood platelet count in patients with active tuberculosis in China. Clinical and Vaccine Immunology. 2011; 18: 629–632.
19. Kirwan DE, Chong DLW, Friedland JS. Platelet Activation and the Immune Response to Tuberculosis. Frontiers in Immunology; 12. Epub ahead of print 19 May 2021. DOI: 10.3389/fimmu.2021.631696.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
